Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscularjunctions
V. Askanas et al., Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscularjunctions, J NE EXP NE, 59(7), 2000, pp. 592-598
Citations number
45
Categorie Soggetti
Neurosciences & Behavoir
Journal title
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
alpha-synuclein (alpha-syn) is an important component of neuronal and glial
inclusions in brains of patients with several neurodegenerative disorders.
Sporadic inclusion-body myositis (s-IBM) is the most common progressive mu
scle disease of older patients. Its muscle phenotype shows several similari
ties with Alzheimer disease brain. a distinct feature of s-IBM pathology is
specific vacuolar degeneration of muscle fibers characterized by intracell
ular amyloid inclusions formed by both amyloid-beta (A beta) and paired-hel
ical filaments composed of phosphorylated tau. We immunostained alpha-syn i
n muscle biopsies of s-IBM, disease-control, and normal patients. Approxima
tely 60% of A beta-positive vacuolated muscle fibers (VMF) contained well-d
efined inclusions immunoreactive with antibodies against alpha-syn. In thos
e fibers, alpha-syn co-localized with A beta, both by light microscopy, and
ultrastructurally. Paired-helical filaments did not contain alpha-syn immu
noreactivity. In all muscle biopsies, alpha-syn was strongly immunoreactive
at the postsynaptic region of the neuromuscular junctions, alpha-syn immun
oreactivity also occurred diffusely in regenerating and necrotic muscle fib
ers. In cultured human muscle fibers, alpha-syn and its mRNA were expressed
by immunocytochemistry, immunoblots, and Northern blots. Our study provide
s the first demonstration that alpha-syn participates in normal and patholo
gic processes of human muscle. Therefore, its function is not exclusive to
the brain and neurodegenerative diseases.